Phase II Pilot Study of Clinical Activity and Proteomic Pathway Profiling of the EGFR Inhibitor, ZD1839 (Iressa; Gefitinib), in Patients With Epithelial Ovarian Cancer or Cervical Cancer
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Gefitinib (Primary)
- Indications Cervical cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Biomarker; Therapeutic Use
- 25 Aug 2005 New trial record.